The efficacy of NeuRecover-SATM(formerly called Tropamineplus;TM, and TropaGenTM) in the treatment of cocaine withdrawal and craving was evaluated at a state psychiatric hospital. This double-blind, placebo-controlled study was conducted in hospitalised patients with a DSM-III-R diagnosis of cocaine dependence. Eight patients received NeuRecover-SATMand 4 patients received placebo. No significant difference in patient demographics was found. The mean number of abstinent symptoms (plusmn; SEM) declined over the first 4 days of treatment, 10.63 plusmn; 1.32 on day 1vs4 plusmn; 1.65 on day 4 in the NeuRecover-SATMgroup compared with 7.25 plusmn; 2.93 on day 1vs4.25 plusmn; 3.61 on day 4 in the placebo group. Cocaine craving in the NeuRecover-SATMgroup on day 1 was 7.88 plusmn; 1.22vs2.71 plusmn; 1.22 on day 4 and 5 plusmn; 2.89 on day 1vs2 plusmn; 1.68 on day 4 in the placebo group. A Mann-Whitney U test showed no statistically significant differences in abstinent symptomatology between or within treatment groups, or treatment effect in the placebo group. However, a significant decrease (p 0.05) in cocaine craving occurred in the NeuRecover-SATMgroup.In conclusion, these preliminary results suggest that NeuRecover-SATMreduces cocaine craving, and larger, longer term studies are warranted.
展开▼
